BNET Industries

Last Fiscal Year Sales:$11.5M
  • Public
  • US
Dow Jones Description

Upon Joe McCarthy's death in 1983, the firm was restructured and renamed McCarthy, Wharton, Wilson & Ethridge. In 1985, Jim Wharton relocated to Annapolis, Maryland and relinquished his partnership, and the firm became McCarthy, Wilson & Ethridge. During the following two years, more space was needed and an addition of 3,000 square feet was added to the 104 South Washington Street office. From 1985 to the present, McCarthy Wilson has expanded greatly. The firm presently consists of nine partners and eleven associates. There are fourteen secretaries, eleven paralegals, eight law clerks, a receptionist, an office manager, and a billing clerk. Because of the expansion of personnel and the need for additional office space, in March of 1997, the property located at 108 South Washington Street was added to the houses belonging to McCarthy Wilson. Being housed in 100, 104 and 108 South Washington Street, in the historic district, provides a unique and pleasant working environment, even though rumor has it that "100" is occupied by a ghost. Several of the firm's employees attest that they have seen a young woman, dressed in white, standing by the fireplace or walking the upper hall. Chuck Wilson denies the existence of a ghostly apparition but everyone notices that his office is strategically located in "104." McCarthy Wilson has remained active in the Peerless Group, an organization dedicated to preserving the historical atmosphere of the sites in Rockville. ...

Interim President and Chief Executive OfficerVaughn M. Kailian
Number of Employees 55
Contact Information

100 Philips Pkwy

Montvale, New Jersey 07645

memorypharm.com

(201) 802-7100

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

News & Analysis

Filter by

memory pharmaceuticals corp. - All News and Analysis

Additional Resources

  • M&A activity continues to recast the industry

    - 2008-12-08

    NEW YORK -- The year is ending in much the same way as it began for the pharmaceutical industry as mergers and acquisitions rule the spotlight. King Pharmaceuticals Inc., for example, announced late last month that it plans to acquire Alpharma Inc. for about $1.6 billion. Johnson &...

  • Roche Buys Memory To Boost Its Pipeline

    - 2008-12-01

    NUTLEY - Swiss drug maker Roche, which has its United States headquarters in the township, last week signed a $50 million deal to buy Memory Pharmaceuticals, its Montvale-based partner in develop- ing a drug for Alzheimer's disease. Memory makes drugs for diseases of the central nervous system, such as Alzheimer's...

  • Has added Memory Pharmaceuticals Corp. to their watch list.

    - 2008-03-12

    M2 PRESSWIRE-12 March 2008-The Maybach Review: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:12032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...

  • Memory Pharmaceuticals Corp. Changes and Reallocates Programs.

    - 2008-03-12

    M2 PRESSWIRE-12 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Changes and Reallocates ProgramsC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have...

  • Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end Results.

    - 2008-03-07

    M2 PRESSWIRE-7 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end ResultsC1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world...

Decision Makers

Name (plus bio) Position
Vaughn M. Kailian Interim President and Chief Executive Officer
David A. Lowe Chief Scientific Officer
James R. Sulat Chief Financial Officer
Stephen R. Murray CMO
Hans-Jnrgen Hess Vice President, Research
Joseph M. Donabauer Controller & Vice President
Jzaneen Lalani Vice President, Legal Affairs
Michael Murray Vice President, Preclinical Drug Development
Michael P. Smith Vice President of Business Development
Jonathan Fleming Co-Founder
Robert I. Kriebel Director

Board of Directors

Name (plus bio) Position
Alix Marduel Board of Directors
Anthony B. Evnin Board of Directors
Larry R Squire Board of Directors
Mark Leschly Board Member
Michael Meyers Board of Directors
Paul Blake Board of Directors
Peter F. Young Board of Directors
Richard Mayeux Board of Directors
Scott Small Board of Directors
Organization Position Status
Memory Pharmaceuticals Corp. Interim President and Chief Executive Officer Current
MPM Capital Limited Partnership General Partner Current
Feinstein Kean Healthcare Current
Cerimon Pharmaceuticals, Inc. Chairman Current
ViaCell, Inc. Chairman Current
California Healthcare Institute, Inc. Chairman Current
Elixir Pharmaceuticals, Inc. Chairman Current
Amylin Pharmaceuticals, Inc. Director Current
Nehi Board of Directors Current
Bioventures, Inc. Director Current
Memory Pharmaceuticals Corp. Board of Directors Current
Cephalon, Inc. Board of Directors Current
Windhover Information, Inc. Director Current
Eisenhower Fellowships Board of Directors Current
Nicox S.A. Director Current
Personalized Medicine Coalition Board of Directors Current
The University of Texas at Austin Member Current
Bioventures, Inc. Member Current
COR Therapeutics, Inc. CEO Former
COR Therapeutics, Inc. President Former
Marion Merrell Dow NA Former
Rigid Building Systems Ltd. Co-Chairman Former
Ikaria, Inc. Chairman of The Ikaria Board of Directors Former
Millennium Pharmaceuticals, Inc. Vice Chairman Former
COR Therapeutics, Inc. Director Former
Biotechnology Industry Organization Director Former
Tufts University B.A. Former
Organization Position Status
Memory Pharmaceuticals Corp. Chief Scientific Officer Current
Alta Partners Chief Scientific Officer and Director Current
Memory Pharmaceuticals Corp. Board of Directors Current
Envivo Pharmaceuticals, Inc. Chief Executive Officer Former
Envivo Pharmaceuticals, Inc. President Former
Roche Bioscience Vice President Former
Roche Bioscience Therapeutic Area Head Former
Envivo Pharmaceuticals, Inc. CNS Former
University of Leeds Ph.D. In Neurobiology Former
University of Bristol B.Sc. Former
Organization Position Status
Alta Partners President, Chief Executive Officer and Director Current
Memory Pharmaceuticals Corp. Chief Financial Officer Current
Intercell Ag Developer Current
Maxygen, Inc. Chairman Current
Maxygen, Inc. Director Current
Intercell Ag Director Current
Momenta Pharmaceuticals, Inc. Board of Directors Current
Memory Pharmaceuticals Corp. Board of Directors Current
Memory Pharmaceuticals Corp. Chief Executive Officer Former
R.R. Donnelley & Sons Co. Chief Financial Officer Former
Chiron Chief Financial Officer Former
R.R. Donnelley & Sons Co. Senior Executive Vice President Former
Moore Wallace Senior Executive Vice President Former
Chiron Vice President Former
Stanford University M.B.A. Former
Yale University B.S. Former
Organization Position Status
Memory Pharmaceuticals Corp. CMO Current
Memory Pharmaceuticals Corp. Vice President, Clinical Dev Former
University of California, San Francisco Residency Department of Psychiatry Former
American Board of Psychiatry and Neurology, Inc. Former
Pfizer Inc. Former
Medical University of South Carolina M.D. and Ph.D. In Molecular Biology Former
University of South Carolina Bachelor of Science Former
Organization Position Status
Memory Pharmaceuticals Corp. Vice President, Research Current
Organization Position Status
Memory Pharmaceuticals Corp. Controller & Vice President Current
Memory Pharmaceuticals Corp. Board of Directors Current
Memory Pharmaceuticals Corp. Principal Former
SPX Corporation Former
Reckitt Benckiser, Inc. Former
Genzyme Corporation Former
Genzyme Biosurgery Former
General Signal Corporation Former

Jzaneen Lalani has served as our Vice President, Legal Affairs since June 2004. From February 2003 to May 2004, Ms. Lalani was a member of the Corporate and Commercial Law Group at Kronish Lieb Weiner & Hellman LLP, where she worked with privately held and publicly traded companies on transactions including mergers and acquisitions, financings and securities offerings. From October 1999 to February 2003, Ms. Lalani was a member of the Business & Technology Group at Brobeck Phleger & Harrison LLP, where her practice also included representing emerging growth companies and newly-public companies. Ms. Lalani received a B.Sc. in 1993 from Queen s University in Ontario, her LL.B. in 1996 from the University of Victoria, in British Columbia, and a Master of International Affairs and a Masters of Law from Columbia University in 1999. Ms. Lalani is admitted to the British Columbia Bar and the New York Bar and is licensed as an in-house counsel in the State of New Jersey.

Organization Position Status
Memory Pharmaceuticals Corp. Vice President, Legal Affairs Current
New Jersey & Company Counsel Current
Kronish Lieb Weiner & Hellman Llp Member Former
Memory Pharmaceuticals Corp. General Counsel Former
Columbia University Masters of Law Former
Columbia University B.Sc. Former
Organization Position Status
Memory Pharmaceuticals Corp. Vice President, Preclinical Drug Development Current

Michael P. Smith, Vice President of Business Development. From 2004 to 2006, Mr. Smith served as Vice President of Business Development for QLT, Inc., a global biopharmaceutical company, where he was responsible for all business development activities as well as corporate strategy. From 1998 to 2004, Mr. Smith was with Chiron Corporation, a biotechnology company, where he held several senior positions, including Manager, Corporate Finance and Business Development and Director Corporate Development, and was responsible for developing and implementing M&A and strategic partnership transactions and strategies. Prior to joining Chiron Corporation, Mr. Smith was the Finance/Business Development Manager for Ascent Logic Corporation, a private systems engineering software company. Mr. Smith holds a B.S. from the University of Virginia, as well as an MBA from the University of California, Berkeley.

Organization Position Status
Memory Pharmaceuticals Corp. Vice President of Business Development Current
Morrison & Foerster LLP summer associate Current
Legalpeople LLC Current
QLT, Inc. Vice President of Business Development Former
Ascent Logic Business Development Manager Former
The Dow Chemical Company Senior Research Scientist Former
American Intellectual Property Law Association member Former
Berkeley Technology Law Journal article editor Former
Chiron Former
United States Patent and Trademark Office Former
California Institute of Technology Ph.D. in Organic Chemistry Former
University of California, Berkeley J.D. Former
University of California, Berkeley MBA Former
University of California, Berkeley A.B. in anthropology Former
University of Virginia B.S. Former

Jonathan J. Fleming is one of our co-founders and is Chairman of our Board of Directors. Mr. Fleming served as Chairman from January 1998 to May 2005 and assumed the position again in October 2006. Mr. Fleming has served as the Managing Partner of Oxford Bioscience Partners, a venture capital firm specializing in life science technology since 1996. Prior to joining Oxford Bioscience, he served as a Founding Partner of MVP Ventures in Boston, Massachusetts. Mr. Fleming serves as a member of the board of directors of Imcor Pharmaceutical Co. (formerly Photogen Technologies, Inc.), a specialty pharmaceutical company focused on developing medical imaging pharmaceutical products. He also serves as Chairman of the board of directors of BioProcessors Corporation, a privately-held corporation, and as a director of seven other privately-held companies, including Leerink Swann & Company, Inc., a Boston-based investment bank specializing in health care companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and is a Senior Lecturer at Massachusetts Institute of Technology's Sloan School of Management. Mr. Fleming received a B.A. from the University of California, Berkeley and a Masters in Public Administration from Princeton University.

Organization Position Status
Memory Pharmaceuticals Corp. Co-Founder Current
Oxford Bioscience Partners Managing Partner Current
Massachusetts Life Sciences Collaborative Managing General Partner, Oxford Bioscience Partners Current
MIT Sloan School of Management Senior Lecturer Current
Massachusetts Institute of Technology Senior Lecturer Current
The Convergence Forum Current
Centagenetix, Inc. Current
Hypnion, Inc. Current
BioProcessors Corp. Chairman Current
Asterand, Plc. Board of Directors Current
Synaptic Pharmaceutical Corp Director Current
Imcor Pharmaceutical Co Board of Directors Current
Nehi Board of Directors Current
Museum of Science Board of Directors Current
Elixir Pharmaceuticals, Inc. Board of Directors Current
Alta Partners Director Current
Railrunner Board of Directors Current
Leerink Swann & Company Board of Directors Current
Braincells, Inc. Board of Directors Current
Museum of Science Trustee Current
Medica Venture Partners Co-Founder Former
Tvm Techno Venture Management General Partner Former
MVP Ventures Founding General Partner Former
Medica Venture Partners Special Limited Partner Former
Oxford Bioscience Partners Owner Former
Biotechnology Venture Investors Group Chairman Former
Princeton University Master's Degree In Public Administration Former
University of California B.A. Former
University of California, Berkeley Bachelor of Arts Degree Former
Organization Position Status
Alta Partners Managing Director Current
Syntonix Pharmaceuticals, Inc. Director Current
Genteric Inc. Board of Directors Current
Corcept Therapeutics Incorporated Member of the Board of Directors Current
Alta Partners Director Current
NeurogesX, Inc. Board of Directors Current
Metabolex, Inc. Board of Directors Current
Memory Pharmaceuticals Corp. Board of Directors Current
Sofinnova Ventures, Inc. General Partner Former
Sofinnova Ventures, Inc. venture career Former
CV Therapeutics Inc. Key Investor Former
Aviron Key Investor Former
Rigid Building Systems Ltd. Key Investor Former
The Medicines Company Key Investor Former
University of Paris Doctorate Former
Stanford University postdoctoral fellowship Former
University of California postdoctoral fellowship Former
University of California, San Francisco Former
The University of California, San Francisco Former

Anthony B. Evnin, Ph.D. , a director since October 2006, is a General Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Icagen, Inc., Infinity Pharmaceuticals, Inc and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Organization Position Status
Venrock Associates Managing General Partner Current
Pharmos Corporation Managing General Partner, Venrock Associates Current
Renovis, Inc. Board of Directors Current
Infinity Pharmaceuticals, Inc Board of Directors Current
Vela Pharmaceuticals, Inc. Current
Infinity Pharmaceuticals, Inc Chair of Infinity's Nominating and Governance Committee Current
Venrock Associates Board of Directors Current
Acceleron Pharma Inc Board of Directors Current
The Rockefeller University Board of Directors Current
Uv Partners Board of Directors Current
Coley Pharmaceutical Group Inc. Board of Directors Current
Icagen, Inc. Board of Directors Current
Alta Partners Director Current
Memory Pharmaceuticals Corp. Board of Directors Current
Pharmos Corporation Director Current
Altea Therapeutics Board Member Current
Metabolex, Inc. Board Member Current
Aveo Pharmaceuticals, Inc. Board of Directors Current
Cancer Immunity Board of Directors Current
Triangle Pharmaceuticals, Inc. Board of Directors Current
Celladon Director Current
Caliper Technologies Board of Directors Current
Syntonix Pharmaceuticals, Inc. Director Current
Sonic Innovations, Inc. Board of Directors Current
Union Carbide Corporation Research Scientist Former
Gilead Sciences, Inc. Former
Sunesis Pharmaceuticals, Inc. Board of Directors Former
IDEXX Laboratories, Inc. Investor Former
Sepracor Inc. Investor Former
Triangle Pharmaceuticals, Inc. Investor Former
Sonic Innovations, Inc. Investor Former
Centocor, Inc. Investor Former
Caliper Life Sciences, Inc. Investor Former
IDEC Pharmaceuticals Investor Former
Massachusetts Institute of Technology Ph.D. in chemistry Former
Massachusetts, Inc. Ph.D. In Chemistry Former
Princeton University A.B. Former
Memory Pharmaceuticals Corp. member Former

Larry R. Squire, Ph.D., University Professor, VA Medical Center in La Jolla, California, and a Professor at the University of California San Diego. Dr. Squire is a leading scientist in the field of human and non-human primate memory. A former President of the Society of Neuroscience, he has helped define the basic distinction between the declarative and non-declarative memory systems of the brain. Dr. Squire sits on the editorial board of Learning & Memory Journal and on the board of directors of the McKnight Endowment Fund for Neuroscience. He was elected Member of the National Academy of Science in 1993. He is the co-author of Memory, From Mind to Molecules.

Organization Position Status
Kansas City VA Medical Center Professor Current
Memory Pharmaceuticals Corp. Board of Directors Current
University of California, San Diego Professor Former
Organization Position Status
Rho Ventures Managing Partner Current
Terahealth, Inc. Managing Partner of Rho Ventures and Serves Current
Medical Present Value Inc. Managing Partner, Rho Ventures Current
Senomyx, Inc. Chairman Current
Medical Present Value Inc. Board of Directors Current
Rho Fund Investors Board Member Current
OraMetrix, Inc. Board Member Current
Memory Pharmaceuticals Corp. Board Member Current
Verenium Corporation - Specialty Enzymes Director Current
Sitv, Inc. Board Member Current
NitroMed, Inc. Director Current
Terahealth, Inc. Board of Directors Current
Diversa Corporation Director Current
NitroMed, Inc. Committee Member Current
Senomyx, Inc. Member Current
Healthcare Ventures, LLC general partner Former
Health Care Ventures LLC General Partner Former
Rho Capital Partners, Inc. Managing Partner Former
Anacor Pharmaceuticals, Inc. Managing Partner of Rho Ventures and Chairman of Anacor's Board of Directors Former
Tercica, Inc. Director Current
Senomyx, Inc. Director Former
Stanford Graduate School of Business M.B.A. Former
Harvard University A.B. Former
Organization Position Status
Dominick & Dominick, LLC Current
Memory Pharmaceuticals Corp. Board of Directors Current
Merrill Lynch & Co., Inc. Director, Biotechnology and Pharmaceutical Investment Banking Former
The Bear Stearns Companies Inc. Former
Lehman Brothers Holdings Inc. Former
D-and_D.Com Former
Manhattan College BS in Accounting Former
Organization Position Status
Memory Pharmaceuticals Corp. Board of Directors Current
Organization Position Status
Intranasal Technology, Inc President and Chief Executive Officer Current
Alphavax, Inc CEO Current
Alphavax, Inc President Current
Memory Pharmaceuticals Corp. Board of Directors Current
Alta Partners Director Current
Intranasal Technology, Inc Board of Directors Current
Positions, Inc. Former
Abbott International LLC Former
Indiana University MBA In Marketing Former
Indiana University BA In History Former

Richard Mayeux is the Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology at Columbia University. He is the director of the Gertrude H. Sergievsky Center and the co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Born in New Orleans, Louisiana, he is a graduate of Oklahoma State University and the University of Oklahoma Health Sciences, School of Medicine. He also holds a masters degree in Epidemiology from Columbia University. He completed residencies in both Internal Medicine (Boston City Hospital, Boston University) and Neurology (Columbia Presbyterian Medical Center, Columbia College of Physicians and Surgeons). He also completed post-doctoral training fellowship in Behavioral Neurology at the Boston Veterans Administration Medical Center (at Boston University) with D. Frank Benson, funded by the National Institute of Health.

Organization Position Status
Sergievsky Center and Co Director Emeritus Current
Sergievsky Center and Co Professor of Neurology, Psychiatry, and Epidemiology Current
Memory Pharmaceuticals Corp. Board of Directors Current
Sergievsky Center and Co Director Current
Columbia University Co-Director Former
Boston City Hospital Residencies Former
Oklahoma State University M.D. in Former
Columbia University Masters Degree In Epidemiology Former
Oklahoma State University B.S. In 1968, Both Former
Organization Position Status
Alta Partners Director Current
Elixir Pharmaceuticals, Inc. Board of Directors Current
Memory Pharmaceuticals Corp. Director Current
US Bioscience Executive Vice President, Chief Financial Officer and Director Former
Neose Technologies, Inc. Chief Financial Officer Former
Neose Technologies, Inc. Senior Vice President Former
Rhone-Poulenc Rorer Former
US Bioscience Director Former
Roanoke College B.S. In Economics Former

Scott Small, M.D., Herbert Irving Assistant Professor in Neurology at Columbia University and Taub Scholar at the Taub Institute. With a background in cellular physiology, Dr. Small has focused on using new imaging modalities to investigate both normal and pathological mechanisms of the brain. Dr. Small was the first investigator at Columbia University to use functional magnetic resonace imaging (fMRI), and he led a team of investigators who published the first paper showing the utility of fMRI for detecting Alzheimer's disease and for characterizing memory decline in the aging population. More recently, he has developed a novel high-resolution application of fMRI, which can be used to investigate physiologic dysfunction in the mouse brain.

Organization Position Status
Memory Pharmaceuticals Corp. Board of Directors Current
Columbia University Investigator Former
Columbia University M.D. Former

Executive News

  • Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors

    Pharma Live - 6/17/09 - View Story

  • Xanodyne names new board member

    TradingMarkets - 6/15/09 - View Story

  • XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference

    SmartBrief - 6/15/09 - View Story

  • Schaeffer's Option Blog: Call Traders Jump on Savient Pharmaceuticals' FDA News

    SmartBrief - 6/13/09 - View Story

  • Abraxis Bioscience Launches ABRAXANE in China for Women with Metastatic Breast Cancer

    SmartBrief - 6/13/09 - View Story

  • Reportlinker Adds R&D Cost Cutting: Managing Cost Containment and Safeguarding Productivity

    SmartBrief - 6/13/09 - View Story

  • GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting

    SmartBrief - 6/13/09 - View Story

  • Jubilant to Work With Endo Pharmaceuticals on Drug Development

    SmartBrief - 6/13/09 - View Story

  • iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

    SmartBrief - 6/13/09 - View Story

  • VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

    SmartBrief - 6/13/09 - View Story

  • Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)

    SmartBrief - 6/13/09 - View Story

  • Pfizer s Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show

    SmartBrief - 6/13/09 - View Story

  • Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors

    Red Orbit - 6/12/09 - View Story

  • Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board...

    Reuters - 6/12/09 - View Story

  • Vaughn Kailian joins Xanodyne board of directors

    Biz Journals - 6/12/09 - View Story

  • Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors

    Street Insider - 6/12/09 - View Story

  • Vaughn Kailian joins Xanodyne board of directors

    Cincinnati Business Courier - 6/12/09 - View Story

  • Valeritas names new CEO

    TradingMarkets - 6/02/09 - View Story

  • Valeritas Announces Appointment of New CEO

    PR Newswire - 6/01/09 - View Story

advertisement
Glass Door

Pharma Industry Companies

Company Employer Rating
Pfizer 3.0
advertisement